Commentary: The NIH ADHD consensus statement: Win, lose, or draw?

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 39, Issue 2, 2000, Pages 194-197

  Jensen, Peter S ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD BEHAVIOR; HEALTH CARE ORGANIZATION; HUMAN; NOTE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0033980222     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200002000-00019     Document Type: Article

References (7)

1. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999), Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:20
2. Hechiman L (1992), Long-term outcome in attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 1:553-565
3. Jensen PS, Hoagwood K (1997), The book of names: DSM-IV in context. Dev Psychopathol 9:231-249
4. Jensen PS, Mrazek D, Knapp P et al. (1997), Evolution and revolution in child psychiatry: ADHD as a disorder of adaptation. J Am Acad Child Adolesc Psychiatry 36:1672-1679
5. MTA Cooperative Group (1999), Fourteen-month randomized clinical trial of treatment strategics for attention deficit hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
6. Pelham WE, Wheeler T, Chronis A (1998), Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 27:190-205
7. Spencer T, Biederman J, WilensT, Harding M, O'Donnell D, Griffin S (1996), Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432